Dren Bio raises $350M to push its own blood cancer drug toward a 2027 launch
What's the deal? Dren Bio has raised $350 million in a late-stage venture round, aiming to get its lead blood cancer drug onto the market by the end of 2027. The California biotech develops bispecific antibodies that direct the immune system's macrophages to engulf diseased cells.
The lead program: DR-01 targets CD94 to clear the cancerous cells of T-cell and natural killer cell lymphomas. It is in a phase 1/2 study in large granular lymphocytic leukaemia and cytotoxic lymphomas.
Why it matters: The raise is a major step-up from Dren Bio's earlier $65 million Series B and gives it the resources to advance its own blood-cancer program rather than rely on a partner. At $350 million, the round ranks in the 99th percentile of all US late-stage venture rounds in health, out of nearly 2,000 tracked.
The track record: Partners have shown unusually strong interest in Dren Bio's cell-depletion approach. Novartis committed $150 million upfront in 2024 for cancer antibody research, while Sanofi paid $600 million upfront for the separate DR-0201 program and later broadened the collaboration.
What could go wrong? Those deals validate the science but do not prove the lead drug will work. DR-01 remains in early clinical testing for rare leukaemias and lymphomas, which makes a 2027 market target ambitious.
The signal: The funding's significance is strategic. With $350 million in hand, Dren Bio can pursue development and commercialization itself — a bid to become a fully integrated biopharmaceutical company rather than a licensing shop.
Read more: endpoints.news
Image credit: Generated with Gemini
